Article
Pfizer and Sangamo Team Up on Hemophilia A Gene Therapy
Author(s):
The companies entered a license agreement that includes Sangamo’s SB-525, one of the company’s lead product candidates for the treatment of Hemophilia A.
Pfizer and Sangamo have entered into an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A. The deal includes SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter, the companies said in a May 10, 2017 press release.
Pfizer will pay Sangamo $70 million upfront and the company will be eligible for additional milestone payments of up to $475 million, and royalties on net sales. Sangamo will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. Pfizer will be operationally and financially responsible for subsequent R&D, manufacturing, and commercialization activities for SB-525 and any additional products.
Source: Sangamo
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
